Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer

The search for novel oncogenes is important because they could be the target of future specific anticancer therapies. In the present paper we report the identification of novel amplified genes in lung cancer by means of global gene expression analysis. To screen for amplicons, we aligned the gene ex...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pathology Vol. 222; no. 1; pp. 89 - 98
Main Authors: Castillo, Sandra D., Angulo, Barbara, Suarez-Gauthier, Ana, Melchor, Lorenzo, Medina, Pedro P., Sanchez-Verde, Lydia, Torres-Lanzas, Juan, Pita, Guillermo, Benitez, Javier, Sanchez-Cespedes, Montse
Format: Journal Article
Language:English
Published: Chichester, UK John Wiley & Sons, Ltd 01-09-2010
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The search for novel oncogenes is important because they could be the target of future specific anticancer therapies. In the present paper we report the identification of novel amplified genes in lung cancer by means of global gene expression analysis. To screen for amplicons, we aligned the gene expression data according to the position of transcripts in the human genome and searched for clusters of over‐expressed genes. We found several clusters with gene over‐expression, suggesting an underlying genomic amplification. FISH and microarray analysis for DNA copy number in two clusters, at chromosomes 11q12 and 13q34, confirmed the presence of amplifications spanning about 0.4 and 1 Mb for 11q12 and 13q34, respectively. Amplification at these regions each occurred at a frequency of 3%. Moreover, quantitative RT–PCR of each individual transcript within the amplicons allowed us to verify the increased in gene expression of several genes. The p120ctn and DP1 proteins, encoded by two candidate oncogenes, CTNND1 and TFDP1, at 11q12 and 13q amplicons, respectively, showed very strong immunostaining in lung tumours with gene amplification. We then focused on the 13q34 amplicon and in the TFDP1 candidate oncogene. To further determine the oncogenic properties of DP1, we searched for lung cancer cell lines carrying TFDP1 amplification. Depletion of TFDP1 expression by small interference RNA in a lung cancer cell line (HCC33) with TFDP1 amplification and protein over‐expression reduced cell viability by 50%. In conclusion, we report the identification of two novel amplicons, at 13q34 and 11q12, each occurring at a frequency of 3% of non‐small cell lung cancers. TFDP1, which encodes the E2F‐associated transcription factor DP1 is a candidate oncogene at 13q34. The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series Accession No. GSE21168. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Bibliography:Spanish Ministerio de Ciencia e Innovación (MICINN) - No. SAF2008-02698
RTICC - No. RD06/0020/0023; No. RD06/0020/0062; No. RD06/0020/1060
istex:2E09ED06DCCF64D4DAB229D1FFA33D5A6CA5D410
ark:/67375/WNG-WJ8S3B3G-F
ArticleID:PATH2732
Supporting Information: Figure S1. Plot of chromosome 13q copy number in one of the two tumours with 13q34 gene amplification using SNP microarraysSupporting Information: Figure S2. Plot for one of the two lung tumours with 11q amplification using SNP microarraysSupporting Information: Figure S3. RT-PCR to test for differential expression among the major isoforms of p120ctn in normal and tumour lungSupporting Information: Table S1. Primer's SequencesSupporting Information: Legends to Figure S1 to S3
No conflicts of interest were declared.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0022-3417
1096-9896
DOI:10.1002/path.2732